Gram Research analysis shows that chronic alcohol consumption damages the heart by reducing a protective protein called DBT, which normally prevents toxic copper from building up inside heart cells. When DBT levels drop, copper accumulates and triggers a harmful cell death process that weakens the heart. Laboratory studies demonstrate that restoring DBT levels or removing excess copper reverses this damage, suggesting new potential treatments for alcohol-related heart disease.
Researchers discovered that chronic alcohol consumption damages the heart through a process involving copper buildup inside heart cells. Using laboratory mice and human heart cells, scientists identified a protein called DBT that normally protects against this copper-related damage. When DBT levels drop due to alcohol exposure, copper accumulates and triggers a harmful cell death process. The study suggests that boosting DBT or reducing copper could offer new ways to treat alcohol-related heart disease, a serious condition affecting millions of heavy drinkers worldwide.
Key Statistics
A 2026 study published in the Journal of Cellular and Molecular Medicine found that mice fed alcohol-containing diets showed significantly reduced DBT protein levels in their hearts compared to control mice.
Research using human heart cells demonstrated that reducing DBT protein induced copper overload and triggered cuproptosis, a copper-dependent cell death process that was reversed by copper-chelating drugs.
Laboratory experiments showed that increasing DBT expression in human heart cells attenuated alcohol-induced copper accumulation and mitochondrial dysfunction with effects comparable to copper-removing medication.
The Quick Take
- What they studied: How chronic alcohol consumption damages heart cells and whether a protein called DBT plays a protective role in preventing that damage
- Who participated: Male laboratory mice fed alcohol-containing diets, human heart cells grown in laboratory dishes, and molecular analysis of genetic material from both sources
- Key finding: Alcohol consumption reduces DBT protein levels in heart cells, allowing toxic copper to build up and trigger a harmful cell death process that weakens the heart
- What it means for you: This research identifies a potential new target for treating alcohol-related heart disease, though human clinical trials are still needed before any new treatments become available
The Research Details
Scientists conducted a multi-step investigation using laboratory mice and human heart cells. First, they fed male mice an alcohol-containing diet to create a model of alcoholic heart disease, then used advanced genetic analysis to identify which genes changed in response to alcohol exposure. They discovered that a gene called DBT was consistently reduced in alcohol-exposed hearts. Next, they studied human heart cells in laboratory dishes, deliberately reducing DBT levels to see what happened. They also tested whether adding back DBT or using a copper-removing drug could reverse the damage. This layered approach allowed researchers to move from whole-animal observations to cellular mechanisms.
This research design is important because it bridges the gap between animal studies and human biology. By confirming findings in both mice and human cells, the researchers strengthened their conclusions. The use of genetic analysis to discover DBT as a key player was more unbiased than simply testing pre-selected genes. Testing both DBT overexpression and copper removal helped clarify whether DBT works specifically through copper regulation or through other pathways.
The study used established laboratory techniques including RNA sequencing (a gold-standard method for measuring gene activity), quantitative PCR (a precise validation method), and Western blotting (a protein measurement technique). The findings were consistent across two independent genetic datasets, which increases confidence. However, the study was conducted entirely in laboratory settings using mice and cells, not human patients, so results may not directly translate to people.
What the Results Show
Mice fed alcohol showed reduced DBT protein levels in their hearts, increased copper accumulation in both blood and heart cells, and weakened heart function. When researchers reduced DBT in human heart cells grown in the laboratory, copper built up inside the cells and triggered a harmful cell death pathway called cuproptosis. This copper accumulation also damaged mitochondria, the energy-producing structures inside cells. Importantly, when researchers either increased DBT levels or used a drug that removes excess copper, they reversed these harmful effects. The protective effects of boosting DBT were similar in strength to the copper-removing drug, suggesting DBT works primarily by controlling copper levels.
The study identified specific molecular markers of cuproptosis that changed in response to alcohol and DBT levels. Mitochondrial dysfunction appeared to be a key mechanism linking copper overload to cell damage. The copper-chelating drug tetrathiomolybdate successfully prevented damage, confirming that copper accumulation is a central problem in alcohol-induced heart injury.
This research adds to growing evidence that cuproptosis, a newly recognized form of cell death, plays a role in various diseases. Previous studies showed that alcohol damages the heart through multiple mechanisms including oxidative stress and inflammation. This study identifies copper-dependent cell death as an additional mechanism, providing a more complete picture of how alcohol harms heart tissue. The finding that DBT regulates this process is novel and opens a new therapeutic avenue.
The study was conducted entirely in laboratory settings using mice and cultured human cells, not living human patients. Results in mice do not always translate directly to humans. The sample size of mice was not specified in the abstract. The study did not test whether increasing DBT in living mice could prevent or reverse alcohol-induced heart damage. Long-term effects and potential side effects of DBT manipulation remain unknown. The research does not address how much alcohol or how long someone must drink before this copper-related damage becomes significant.
The Bottom Line
Based on this research, people with heavy alcohol consumption should be aware that alcohol damages the heart through multiple mechanisms, including copper buildup. The strongest evidence-based recommendation remains reducing or eliminating alcohol consumption. While this research suggests DBT-boosting or copper-removing drugs might help, these are not yet available treatments and require human clinical trials first. Anyone with alcohol-related heart disease should work with a cardiologist on proven treatments.
This research is most relevant to people who drink heavily and have heart problems, researchers studying alcohol-related disease, and pharmaceutical companies developing new heart disease treatments. It may eventually matter to anyone at risk for alcoholic cardiomyopathy. It does not directly apply to moderate drinkers or people without heart disease.
In laboratory settings, the protective effects of DBT appeared within the timeframe of cell culture experiments (typically days to weeks). In living mice, changes in heart function would take weeks to months. If new treatments based on this research are developed, human clinical trials would take several years before any medication becomes available to patients.
Frequently Asked Questions
How does alcohol damage the heart at the cellular level?
Alcohol reduces a protective protein called DBT, allowing toxic copper to accumulate inside heart cells. This copper buildup triggers a cell death process called cuproptosis that damages mitochondria and weakens heart function.
What is cuproptosis and why does it matter for heart health?
Cuproptosis is a newly discovered form of cell death triggered by copper overload. In alcohol-exposed hearts, this process damages heart cells and contributes to weakened cardiac function, making it a key mechanism of alcohol-related heart disease.
Could DBT-boosting drugs treat alcoholic heart disease?
Laboratory studies suggest DBT-boosting could help, but human clinical trials have not yet been conducted. Current proven treatments for alcoholic heart disease focus on reducing alcohol consumption and managing heart failure symptoms.
How much alcohol causes this type of heart damage?
This study does not specify a threshold amount of alcohol that triggers copper-related damage. Heavy chronic alcohol consumption is associated with alcoholic cardiomyopathy, but individual risk varies based on genetics, overall health, and drinking patterns.
Is this research applicable to humans or just laboratory animals?
The research was conducted in mice and human cells grown in laboratories. While findings are promising, human clinical trials are needed to confirm whether these mechanisms apply to living people and whether new treatments would be safe and effective.
Want to Apply This Research?
- Track daily alcohol consumption in standard drinks and monitor heart-related symptoms including shortness of breath, chest discomfort, or unusual fatigue. Record these alongside any cardiac testing results from your doctor.
- Set a daily alcohol limit using the app’s goal-setting feature and receive reminders about the connection between alcohol reduction and heart health. Use the app to track progress toward reducing consumption and celebrate alcohol-free days.
- Establish a long-term tracking system that correlates alcohol consumption patterns with heart health markers from medical visits, such as ejection fraction or exercise tolerance. Review monthly trends to identify whether reducing alcohol correlates with improved cardiac function.
This research describes laboratory findings in mice and human cells, not clinical outcomes in human patients. The study does not yet provide evidence for new treatments available to people. Anyone with alcohol-related heart disease or concerns about their heart health should consult with a cardiologist or healthcare provider. This article is for educational purposes and should not replace professional medical advice. Do not attempt to self-treat based on these findings, as DBT-boosting or copper-chelating treatments are not yet established therapies for human patients.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.